Dermatomyositis
Conditions
Keywords
Dermatomyositis
Brief summary
Dermatomyositis is a rare chronic autoimmune and inflammatory disease that affects the skin and striated muscles. Its prognosis is linked to visceral involvement (lungs, heart, and oropharyngeal region) and to the possible presence of associated cancer. The implementation of the research will allow identification of incident cases of dermatomyositis in Guadeloupe and the characterization of the disease in the overseas population, in the absence of data in the literature.
Detailed description
In the French West Indies, this condition is associated with high short- and medium-term morbidity and mortality. Diagnostic delays and patient care pathways may help explain this. However, a particularly severe phenotype of the disease in Antillean patients may also play a role, as observed in other autoimmune and inflammatory diseases we have described in overseas populations (e.g., systemic sclerosis, sarcoidosis). Identifying factors associated with the severity of dermatomyositis at the time of diagnosis would allow for the early implementation of a tailored management strategy to improve the disease prognosis in the target population.
Interventions
None listed
Sponsors
Centre Hospitalier Universitaire de la Guadeloupe
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with a diagnosis of dermatomyositis according to the 2003 ENMC criteria * Patient with parents or grandparents originating from the Caribbean arc * Patient aged 16 years or older * Patient residing in Guadeloupe * Patient (or legal representative) who has received information about the study and has signed the informed consent form * Patient affiliated with a social security scheme
Exclusion criteria
* Patient who started treatment with intravenous immunoglobulins, corticosteroids, or immunosuppressants within the month prior to the diagnosis of dermatomyositis * Patient under legal protection (guardianship or trusteeship) or deprived of liberty
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| severity of dermatomyositis at diagnosis | Assessed at baseline (diagnosis). | The primary outcome measure is the severity of dermatomyositis at diagnosis, defined by the presence of one or more of the following criteria: Muscle involvement resulting in functional disability; Associated visceral involvement, including the heart, lungs, or oropharyngeal region; Associated cancer, either previously diagnosed within the past three years or diagnosed concurrently with dermatomyositis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | Assessed over 2 years from the date of dermatomyositis diagnosis | Number of participants who die from any cause during the follow-up period. Units: Count of participants |
| Relapse Occurrence | Assessed over 2 years from the date of dermatomyositis diagnosis | Number of participants experiencing relapse(s) during treatment tapering or after treatment discontinuation. Units: Count of participants |
| Cancer Occurrence | Assessed over 2 years from the date of dermatomyositis diagnosis | Number of participants diagnosed with any cancer during the follow-up period. Units: Count of participants |
Countries
Guadeloupe
Contacts
Primary Contactmelanie petapermal, Master degree
Backup ContactValérie Hamony Soter
Outcome results
None listed